Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Kim, Jae-Hui; Kim, Jong-Woo; Kim, Chulgu

doi:10.3390/jcm10163580

Cited by 5 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a cohort study of MrOS with 4130 participants showed that patients with hip arthritis or total hip arthroplasty were 1.27 times more likely to be frail than healthy men (95% CI 1.19:1.38) [40]. A crosssectional study of 582 elderly people over 65 years old from Spain showed that frailty was associated with a variety of bone and joint diseases, including OA [41]. A recent review reported that frailty may interfere with the in ammatory environment of normal tissues, thereby hindering joint repair and ultimately leading to the development of OA.…”

Section: Discussionmentioning

confidence: 99%

Causal association between frailty and arthritis: a bidirectional two-sample Mendelian randomization analysis

Yan

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Epidemiological data suggest close associations between frailty and osteoarthritis (OA) and rheumatoid arthritis (RA). However, whether these associations are causal is unclear. We therefore conducted a bidirectional Mendelian Randomization (MR) study to assess the causal relationship between frailty and OA and RA. Methods We extracted the summary genome-wide association statistics data of individuals of European ancestry for FI (N = 175266), OA (826690), and RA (58284). The two-sample MR analysis was primarily conducted using the inverse variance weighting method (IVW), followed by heterogeneity testing and sensitivity analysis. Results Genetically determined FI was significantly associated with an increased risk of all OA [odds ratio (OR) = 1.47, 95% confidence interval (CI) = 1.21 to 1.78, P < 0.001] and knee OA [OR = 1.78, 95% CI = 1.30 to 2.45, P < 0.001] but was not associated with hip OA [OR = 1.24, 95% CI = 0.97 to 1.59, P = 0.092] and RA [OR = 1.10, 95% CI = 0.73 to 1.66, P = 0.635]. In the reverse direction analysis, genetically determined all OA [beta = 0.22, 95% CI = 0.14 to 0.29, P < 0.001], hip OA [beta = 0.03, 95% CI = 0.01 to 0.05, P = 0.002], knee OA [beta = 0.10, 95% CI = 0.06 to 0.14, P < 0.001], and RA [beta = 0.03, 95% CI = 0.02 to 0.04, P < 0.001] showed significant associations with an increased risk of FI. The results were stable across sensitivity and validation analyses. Conclusion Our results indicate that frailty increases the risk of both all OA and knee OA but not hip OA and RA. In the reverse MR study, both OA and RA increased the risk of FI.

show abstract

Section: Discussionmentioning

confidence: 99%

Causal association between frailty and arthritis: a bidirectional two-sample Mendelian randomization analysis

Yan

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…However, several investigators have raised concerns regarding the potential side effects of VEGF reduction, especially in elderly patients [32][33][34] . In fact, several studies have suggested some impact of this concern in clinical practice 35,36 .…”

Section: Importance Of Predicting the Difference In Post-treatment Oc...mentioning

confidence: 99%

Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network

Moon

Lee

Hwang

et al. 2023

Sci Rep

View full text Add to dashboard Cite

To develop an artificial intelligence (AI) model that predicts anti-vascular endothelial growth factor (VEGF) agent-specific anatomical treatment outcomes in neovascular age-related macular degeneration (AMD), thereby assisting clinicians in selecting the most suitable anti-VEGF agent for each patient. This retrospective study included patients diagnosed with neovascular AMD who received three loading injections of either ranibizumab or aflibercept. Training was performed using optical coherence tomography (OCT) images with an attention generative adversarial network (GAN) model. To test the performance of the AI model, the sensitivity and specificity to predict the presence of retinal fluid after treatment were calculated for the AI model, an experienced (Examiner 1), and a less experienced (Examiner 2) human examiners. A total of 1684 OCT images from 842 patients (419 treated with ranibizumab and 423 treated with aflibercept) were used as the training set. Testing was performed using images from 98 patients. In patients treated with ranibizumab, the sensitivity and specificity, respectively, were 0.615 and 0.667 for the AI model, 0.385 and 0.861 for Examiner 1, and 0.231 and 0.806 for Examiner 2. In patients treated with aflibercept, the sensitivity and specificity, respectively, were 0.857 and 0.881 for the AI model, 0.429 and 0.976 for Examiner 1, and 0.429 and 0.857 for Examiner 2. In 18.5% of cases, the fluid status of synthetic posttreatment images differed between ranibizumab and aflibercept. The AI model using GAN might predict anti-VEGF agent-specific short-term treatment outcomes with relatively higher sensitivity than human examiners. Additionally, there was a difference in the efficacy in fluid resolution between the anti-VEGF agents. These results suggest the potential of AI in personalized medicine for patients with neovascular AMD.

show abstract

“…Previously, photodynamic therapy (PDT) was used as the primary treatment option for this condition. However, anti-vascular endothelial growth factor (VEGF) therapy has widely replaced PDT as an effective first-line treatment for PCV [2,3].…”

Section: Introductionmentioning

confidence: 99%

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy

Jeon

Kim

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Background: To evaluate the short-term outcomes of switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy (PCV). Methods: This retrospective study included 18 eyes diagnosed with aflibercept-resistant PCV. All patients were treated with two to four consecutive ranibizumab injections at 4–5-week intervals. The best-corrected visual acuity (BCVA), and central retinal thickness (CRT) values before and after switching to ranibizumab were compared. The proportion of eyes showing ≥100 µm decrease in retinal thickness and/or complete resolution of fluid after switching was identified. Results: The mean number of aflibercept injections before switching was 5.7 ± 3.3. After switching, a mean of 2.8 ± 0.6 consecutive ranibizumab injections was performed. The mean logarithm of minimal angle of resolution (logMAR) BCVA was 0.41 ± 0.26 (Snellen equivalents = 20/51) before switching, and 0.40 ± 0.30 (20/50) after switching (p = 0.574). The mean CRT was 422.2 ± 152.4 µm before switching, and 400.7 ± 182.0 µm after switching (p = 0.236). A decrease in CRT of ≥100 µm, and/or complete resolution of fluid was noted in three eyes (16.7%). Conclusions: Switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy was not effective in most patients, suggesting the need for further investigation to seek more effective treatment options for this condition.

show abstract

Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Cited by 5 publications

References 35 publications

Causal association between frailty and arthritis: a bidirectional two-sample Mendelian randomization analysis

Causal association between frailty and arthritis: a bidirectional two-sample Mendelian randomization analysis

Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy

Contact Info

Product

Resources

About